Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. - Wikidata - awgldk - TriplyDB

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

http://www.wikidata.org/entity/Q36834545

about

Melanoma-associated leukoderma - immunology in black and white?Cancer vaccines Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology CTLA4 blockade broadens the peripheral T-cell receptor repertoire Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.Trends in cancer immunotherapy Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro.Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.Therapeutic cancer vaccines: are we there yet?Fusion of ubiquitin to HIV gag impairs human monocyte-derived dendritic cell maturation and reduces ability to induce gag T cell responses.IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity.Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10.Enhancement of dendritic cells as vaccines for cancer Immunotherapy for melanoma: current status and perspectives.An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer.Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Update on vaccine development for renal cell cancer.Lessons learned from cancer vaccine trials and target antigen choice New insights on adenovirus as vaccine vectors.The evolving role of dendritic cells in cancer therapy.Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.Directing dendritic cell immunotherapy towards successful cancer treatment.Dendritic cells: are they clinically relevant?Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?New approaches to the development of adenoviral dendritic cell vaccines in melanoma.Engineering dendritic cells to enhance cancer immunotherapy.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.NK cells: key to success of DC-based cancer vaccines?Immune biomarkers: how well do they serve prognosis in human cancers?Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy.Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma.

P2860

Q26850001-A14B0F8B-4CDB-4457-8A21-3493603814B5 Q27024438-4326AD98-DC69-4BB9-9002-36EDB7E2265B Q28744503-CBAF7EA6-8F95-435F-820B-4CDE00C7DF4C Q30426385-2D35EBF5-48D4-48DD-8671-3D9158571553 Q30438965-78A24DDF-14AB-41E5-94FC-7C51AF19631E Q33560753-2CBD05AF-6142-4D8D-ABBB-4E39FA7BEEC3 Q33907628-7926FF28-FEFF-419E-AACD-E568CBEBC368 Q33913101-62ACE4EE-7374-4A52-8865-E2BE4A4A3665 Q34052702-BAF6A713-24AC-46E6-B047-0D703F88F0EB Q34066925-4232B421-DFAA-4D00-A3E9-F58D9473EB43 Q34627677-3970180F-88EE-4FE3-B806-42AD1E12316A Q34661815-90ED5F63-C87A-4291-84E9-A2707344B111 Q34786691-D464095F-8F59-4309-8B4E-8C12FD58834D Q35088691-162439F1-3E11-4902-A443-9C8D1FF5B212 Q35156105-EB3BAF14-172F-4395-BA7A-C0EEC072A09B Q35871590-69DD778E-DEE7-4404-94B0-CAEF32DAA6B0 Q35883106-A7BAD97C-7F8F-48BD-9D91-53257E54B676 Q36057449-9FF290A9-D338-4FF5-8E6A-9AB6544E9257 Q36209210-C15E77A9-2208-4607-B7A3-C46CC12B0941 Q36453216-32A75D39-21D8-4E3D-8927-83815CFAB447 Q36476387-41CB5FEE-BAAE-47E8-ABA1-A0A062B8BC42 Q36547213-D85C450B-D1A0-4688-9209-2FA312AF6B99 Q36567448-7A053643-F1C9-457E-B1D0-9E4B822FBD5C Q36989720-BCE30BFE-BAD1-424E-BE3B-C2D8A4850D86 Q37033762-8859DCD9-4213-4DEA-9077-394E657ED2D4 Q37513550-B09CF7B6-7583-4B5A-BE63-1E9D402E9574 Q37687418-D998C2B9-EDE0-489B-A962-3933D9C05856 Q37727967-AA822648-80B0-4397-B066-93E0DD500D73 Q37754014-77E67FCD-014F-4512-ADCF-D946AD2376D9 Q37778692-B7AC5979-478F-4AD9-B31D-66D7969689F5 Q37800934-EC188769-4464-4C8C-ACA2-F2F16EBCD2B7 Q37820489-EE4FFFF7-2B04-4154-BACD-1F19BE52D6BA Q37862064-3F0125D0-EC58-4512-BAB5-86B787FA99EC Q37952804-A855FF83-A27F-43B1-B6CD-F6127B226EBA Q37974160-9D2F2F51-703E-44CE-B839-AA16CD7E0684 Q37989571-7639FC5E-575E-471C-BFBB-8E61A61AC6C3 Q38036202-A782B2E1-2A5A-4DF0-B160-17385FD2AAF3 Q38262757-899A6CED-65B1-414C-8B5F-999B83278A62 Q39037222-8E4156F9-6104-418D-B5EE-51F2666B643D Q39575914-654DFA1C-6967-4737-8C09-2D153E11D29A

P2860

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

http://www.wikidata.org/entity/Q36834545

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

@en

type

label

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

@en

prefLabel

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

@en

P1433

Q36834545-EE79C9E1-57A5-461C-866E-40FD12CF7CC1

P1476

Q36834545-38DF5CF2-9EC8-49F6-8653-C07031126145

P2093

Q36834545-36DCA745-98D0-4C43-9F7D-61828041AA74

Q36834545-47704391-D7F2-490E-B91B-240BED64C61E

Q36834545-7A2C3FF0-DBA3-4E83-AE9F-EA3ABBD2BD2D

Q36834545-82A5ADD6-BD1F-4C3E-A1AF-636B4FC82E07

Q36834545-A9EC8ED3-7486-4D22-BE28-BEA389D9D9EE

Q36834545-BD19F541-E1D5-4B3A-976D-0C866EC7CA0A

Q36834545-BF63BC5A-D6A8-4549-A831-CCF6D5235DE2

Q36834545-C989B69E-EE0C-4525-88C0-A901FAE0F65B

Q36834545-D1C76C03-2631-498D-9F79-5AB93EB57EFA

Q36834545-D8A2DD94-8785-4535-8E72-D67AC9C4996E

P2860

Q36834545-0D2F3E33-1EA9-452B-95EB-B3E159985909

Q36834545-109E7D4A-4111-4537-8B6B-5C68E2703F51

Q36834545-122AAD19-86EF-4AC0-952E-EA1D991009B8

Q36834545-1545ECDD-1439-4B2A-92D3-AEB322FE8899

Q36834545-1BA6F26B-527D-4B93-820A-E1C7156A0500

Q36834545-1F74C5D8-665D-4FBC-A24D-B74DE3F1AF4F

Q36834545-2469CDDB-9BE1-479E-A6D7-F09604710A59

Q36834545-2BC75272-D4A3-454F-9B34-3DB6F91E38BF

Q36834545-345BB040-A905-4631-9D19-CB73ABD9C9A7

Q36834545-3CEC861E-8F50-4507-82C9-49884F0CAA47

P304

Q36834545-80CF1C81-0F2C-4FE5-A63F-E5937638A533

P31

Q36834545-B8D38246-7136-4C19-9506-CF172880A768

P356

Q36834545-746CA240-63FB-4A6C-B0BD-E14C41429BBE

P433

Q36834545-20053A1D-DAA0-44A1-B4C4-0FFD16BC6646

P478

Q36834545-2173CDCE-326F-4452-AE4F-5E9122638A59

P577

Q36834545-3568AC22-1947-4A93-816A-0EACF08BCFF3

P698

Q36834545-521855E5-1FC3-406A-AA78-F5013331F138

P921

Q36834545-1047D3AC-10B7-42C9-8B4B-641D9AE70765

P932

Q36834545-1EE50133-707D-4DD2-A8F2-FDF6AAC093A0

P356

CJI.0B013E31816A8910

P1433

Journal of Immunotherapy

P1476

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

@en

P2093

Antoni Ribas

http://www.w3.org/2001/XMLSchema#string

Begonya Comin-Anduix

http://www.w3.org/2001/XMLSchema#string

Denise K Oseguera

http://www.w3.org/2001/XMLSchema#string

Douglas M Potter

http://www.w3.org/2001/XMLSchema#string

Elizabeth Seja

http://www.w3.org/2001/XMLSchema#string

Hong T Vu

http://www.w3.org/2001/XMLSchema#string

James S Economou

http://www.w3.org/2001/XMLSchema#string

Jin-Quan Yang

http://www.w3.org/2001/XMLSchema#string

John A Glaspy

http://www.w3.org/2001/XMLSchema#string

Lazar Vujanovic

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

Dendritic cells and the control of immunity

Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles

The dendritic cell system and its role in immunogenicity

CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease.

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.

T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.

Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway

P304

294-309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CJI.0B013E31816A8910

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18317358

http://www.w3.org/2001/XMLSchema#string

P921

P932

3651040

http://www.w3.org/2001/XMLSchema#string